drugset / Trial / NCT02458092
Evaluate the Safety and Efficacy of Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered With Adjuvant AS01B
Phase 1
Completed
30 enrolled
U.S. Army Medical Research and Development Command
GlaxoSmithKline · collabKenya Medical Research Institute · collabUnited States Agency for International Development (USAID) · collabWalter Reed Army Institute of Research (WRAIR) · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to determine whether an investigational malaria vaccine is safe and induces an immune response against malaria when tested in adults living in the United States.
Timeline
- Start
- 2008-04
- Primary completion
- 2008-12
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FMP010 | Vaccine | 50 ug | Intramuscular |
| Subject | Rabies vaccine | Vaccine | 1 ml | Intramuscular |